Objective: To investigate whether the incidence of cervical intraepithelial neoplasia (CIN), in particular of high grade CIN, increased in Berlin during the period 1970-1989 and whether the ages of women with CIN had decreased.

Study Design: In the former German Democratic Republic, which had a highly centralized public health system, all gynecologic operations performed on women living in the Mitte district of Berlin were carried out during the period 1970-1989 (when the Berlin Wall fell) in the gynecologic clinic of the Charité Hospital.

Results: The incidence of all CIN increased from year to year over the observation period: 0.04% (1970-1971), 0.10% (1980-1981), 0.39% (1988-1989). There was a particularly high increase in the incidence of high grade intraepithelial neoplasms (CIN 3): 0.016% (1970-1971), 0.056% (1980-1981), 0.25% (1988-1989). With a virtually unchanged age distribution for women in the Mitte district of Berlin, the median age of women with CIN 3 decreased significantly from 1970 to 1989, from 39.5 (1970) to 33 (1989) (P < .001).

Conclusion: The increase in the incidence of CIN, especially of high grade CIN, as well as the reduction in age for onset of the disease, makes high participation in screening necessary, above all among young women.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000330976DOI Listing

Publication Analysis

Top Keywords

mitte district
12
district berlin
12
high grade
12
incidence cervical
8
cervical intraepithelial
8
intraepithelial neoplasia
8
young women
8
women mitte
8
cin
8
cin high
8

Similar Publications

Background: Acute variceal bleeding (AVB), a life-threatening complication of liver cirrhosis, can be effectively treated by endoscopy, but there is a risk of early rebleeding after endoscopic variceal treatment (EVT). Thrombocytopenia is the most common hemostatic abnormality in liver cirrhosis. However, it is still unclear about whether thrombocytopenia increases the failure of EVT in cirrhotic patients with AVB.

View Article and Find Full Text PDF

Background: The planning and implementation of intervention measures against schistosomiasis, particularly mass administration, require knowledge of the current status of the infection. This is important for monitoring the impact of the intervention on disease indicators such as a decline in infection prevalence, intensity of infection, and urogenital morbidities. Following repeated rounds of mass treatment in northwestern Tanzania, the epidemiology of urogenital schistosomiasis has changed; thus, for the effective planning and allocation of resources, it is important to understand the current status of the disease in the targeted groups.

View Article and Find Full Text PDF

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Cardiovasc Diabetol

March 2024

Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.

Article Synopsis
  • The 9th Cardiovascular Outcome Trial (CVOT) Summit took place online from November 30 to December 1, 2023, focusing on recent outcomes trials involving medications like dapagliflozin, semaglutide, and bempedoic acid aimed at reducing major cardiovascular events and improving metabolic health.
  • A diverse group of healthcare professionals discussed updates in the management of cardiovascular disease in patients with diabetes, heart failure, and chronic kidney disease, alongside the latest treatments for type 1 diabetes and obesity.
  • The Summit emphasized the need for diversity in clinical trial participants and the importance of patient-reported outcomes, advocating for personalized treatment strategies and the integration of continuous glucose monitoring technology in managing diabetes
View Article and Find Full Text PDF

Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide. The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. There are numerous effective medications for modifying CAD but new pharmacologic therapies require increasingly large and expensive cardiovascular outcome trials to assess their potential impact on MACE and to obtain regulatory approval.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!